Acumen Pharmaceuticals (ABOS)
Develops sabirnetug, an investigational antibody for early symptomatic Alzheimer’s disease.
Something off on this page? Send us feedback.
Develops sabirnetug, an investigational antibody for early symptomatic Alzheimer’s disease that selectively targets toxic soluble amyloid-beta oligomers. Its central program is the ALTITUDE-AD clinical trial, while formulation and delivery initiatives seek to extend the program.
Develops sabirnetug, a humanized monoclonal antibody designed to selectively target toxic soluble amyloid-beta oligomers in early symptomatic Alzheimer’s disease.
The program rests on long-running research into these oligomers and is being evaluated in ALTITUDE-AD, a Phase 2 trial of intravenous sabirnetug that spans the United States, Canada, the European Union, and the United Kingdom.
The company is also investigating a subcutaneous formulation and has described a development initiative using blood-brain-barrier technology.
With no approved commercial product identified in the dossier, operations depend on completing and reporting ALTITUDE-AD and continued development of sabirnetug, its formulation, and delivery initiatives.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
No analyst notes in the last 24 months.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $110.2M · Total debt $31.6M · Total assets $116.0M · Shareholders' equity $57.3M
- Revenue
- $0
- Operating income
- −$32.6M
- Net income
- −$32.7M
No dividends on record.
| Institutions | 66.34% | 47.97M shares | |
|---|---|---|---|
| 99 holders · as of Jun 30, 2026 | |||
| Insiders | 8.61% | 6.23M shares | |
| 15 holders · as of Jun 17, 2026 | |||
| Strategic holders | 4.73% | 3.42M shares | |
| 1 holder · as of Aug 13, 2025 | |||
| Other | 20.32% | 14.70M shares | |
| remainder | |||
72.32M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Ra Capital Management, L.P.Institution | 29.03% | 20.99M | as of Jun 30, 2026 |
Sands Capital Ventures, LLCInstitution | 5.14% | 3.72M | as of Jun 30, 2026 |
James B. Murray Jr.Insider | 4.99% | 3.61M | filed Apr 7, 2026 |
Sands Capital Alternatives, LLCStrategic | 4.73% | 3.42M | filed Aug 13, 2025 |
BlackRock, Inc.Institution | 3.44% | 2.49M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 16, 2026 | Derrell Porter | director | −12,800 | $2.33 |
| Jun 17, 2026 | Derrell Porter | director | −13,040 | $2.33 |
| Jun 15, 2026 | Derrell Porter | director | −6,460 | $2.35 |
| Jun 9, 2026 | Nathan B. Fountain | director | −6,400 | $2.23 |
| Mar 6, 2026 | Derek M. Meisner | officer: Chief Legal Officer & Corp Sec | −2,090 | $3.26 |
- Eli Lilly
Approved anti-amyloid therapy for early symptomatic Alzheimer's disease
- Biogen
Co-commercialized anti-amyloid antibody for early Alzheimer's disease
- AC Immune
Clinical-stage active anti-Abeta immunotherapy for Alzheimer's disease
- Annovis Bio
Pivotal-stage oral therapy candidate for early Alzheimer's disease
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Acumen Pharmaceuticals | $2.63 | +1.35% | $187.1M | — | — | — | — |
| Eli Lilly | $1,171.49 | +0.57% | $1.10T | 39.1 | 28.6 | 13.8 | +47.7% |
| Biogen | $225.22 | +2.81% | $32.37B | 38.8 | 17.0 | 3.3 | +3.4% |
| AC Immune | $2.72 | +2.26% | $270.2M | — | — | 12.6 | +823.6% |
| Annovis Bio | $1.27 | +6.72% | $50.6M | — | — | — | — |
| Median | 38.9 | 22.8 | 12.6 | +47.7% |